2016-17: A Percolating Pipeline — While scaling up access to all treatment and prevention options that currently exist is essential, it is not sufficient. There remains a critical need for additional options. In addition to the introduction of oral TDF-based PrEP and the open-label extension studies of the vaginal dapivirine ring, there are a number of efficacy trials planned or underway (noted below). They're tackling virtually every intervention — from next-generation PrEP in the form of F/TAF, a drug that will soon be tested for efficacy as daily oral PrEP, to long-acting injectables, vaccines and antibody-mediated prevention.

Strategy	Trial	Product	Number participants	Population	Status start–end	Location
Antibody	HVTN 704/ HPTN 085	VRC01 antibody, infused every two months	2,700	Men and transgender persons who have sex with men	Enrolling Apr 2016—Sept 2020	Brazil, Peru, US
Antibody	HVTN 703/ HPTN 081		1,500	Sexually active women	Enrolling May 2016—Jul 2020	Botswana, Kenya, Malawi, Mozambique, Tanzania, South Africa, Zimbabwe
Preventive HIV vaccine	HVTN 702	ALVAC/gp120 MF59 adjuvant boost, five doses over 12 months	5,400	Sexually active heterosexual women and men	Planned Nov 2016–End 2020	South Africa
Long-acting injectable	HPTN 083	Cabotegravir injections every two months	4,500	Men and transgender persons who have sex with men	Planned Q4 2016–June 2020	~40 sites in North and South America, South Africa and Asia
Oral PrEP	Discover	Daily F/TAF	5,000	Men and transgender women who have sex with men	Planned Q4 2016—End 2020	Over 90 sites in Canada, Europe and the US
Long-acting injectable	HPTN 084	Cabotegravir injections; schedule to be confirmed, either every two or three months	TBD	Sexually active women	Potential start in 2017	Southern and East African countries TBD
Preventive HIV vaccine	TBD	Ad26/MVA boost	TBD	TBD	Potential start in 2017	US, Latin American, Southern and East African countries TBD